Clinical Trial Update: Fibroblast Growth Factor (FGFs) / Fibroblast Growth Factor Receptor (FGFRs) Genetic as a Second-line Therapy for Recurrent / Progressive Gastric Cancer With INCB054828 and Paclitaxel a Study to Evaluate the Safety and Efficacy of Combination Therapy. [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 clinical trial evaluated the safety and efficacy of combining erdafitinib (INCB054828) with paclitaxel as second-line therapy for gastric …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• INCB054828 (erdafitinib)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Yonsei University | Conditions: Fibroblast Growth Factors (FGFs)/Fibroblast Growth Factor Receptors (FGFRs) Genetic Aberration Gastric Cancer, INCB054828, Paclitaxel | Phase 1, Phase 2 | Status: COMPLETED